SAFETY OF PEDIATRIC COMBINATED VACCINE FOR DIPHTHERIA, PERTUSSIS, TETANUS, POLIO AND HAEMOPHILUS INFLUENZA TYPE B IN THE PRIMARY IMMUNIZATION AND FIRST BOOSTERISATION

• Main Authors: N. D. Chernova (Author), I. A. Ivanova (Author), G. M. Demchuk (Author), Y. E. Cousina (Author), O. B. Valetova (Author)
• Format: Book
• Published: Union of pediatricians of Russia, 2012-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1727-5776; 2500-3089; 10.15690/pf.v9i4.387
• Keywords: safety; dtap-ipv//hib; vaccination; evaccination; Pediatrics; RJ1-570; Therapeutics. Pharmacology; RM1-950
• Source: Педиатрическая фармакология, Vol 9, Iss 4, Pp 32-35 (2012)

The results of studies of the safety of a combined five-component pediatric vaccine to prevent diphtheria, pertussis, tetanus, polio, Haemophilus influenzae type b (DTaP-IPV//Hib) in children in the primary vaccination and for the first boosterisation are shown. On the introduction of 208 doses of 264 (75.8%) there were no any local or general reactions registered. The registered local or general reactions occurred usually on the 1st day after vaccination and lasted for 1-2 days. Local reactions with a diameter ≥ 2 cm were reported in 2 cases (0.8%) and did not exceed the diameter of 2 cm. Increased body temperature ≥ 38,5°C was recorded in 3 cases (1.1%) and was not higher than 39,0°C. There have been fixed no cases of anaphylactic reactions, seizures, encephalitic reactions. Due to the high-profile security vaccine DTaP-IPV//Hib is suitable for wide application in outpatient conditions for the standard routine and catch-up vaccination of healthy children and children with underlying medical conditions.